Intranasal administration of ngf for the treatment of sensorineural hearing loss

A method of preventing or treating sensorineural hearing loss in a subject, the method comprising intranasally administering to the subject a pharmaceutical composition comprising NGF or mutein thereof having the amino acid sequence of SEQ ID NO:

• 3, SEQ ID NO:
• 4, SEQ ID NO:
• 5 or SEQ ID NO:
• 6, and at least one pharmaceutically acceptable excipient.

A pharmaceutical composition, comprising:

• NGF or mutein thereof having the amino acid sequence of SEQ ID NO:
• 3, SEQ ID NO:
• 4, SEQ ID NO:
• 5 or SEQ ID NO:
• 6, preferably at a concentration between 5 μg/ml and 1 mg/ml, more preferably between 10 μg/ml and 400 μg/ml, even more preferably between 15 μg/ml and 200 μg/ml,
• NaH2PO4*H2O, preferably at a concentration between 5 and 8 mg/ml, more preferably of 6.9 mg/mL,
• NaCl, preferably at a concentration between 5 and 6.5 mg/ml, more preferably of 5.84 mg/mL,
• Poloxamer 188, preferably at a concentration between 0.05% w/v and 0.2% w/v, more preferably of 0.1% w/v,
• L-Methionine, preferably at a concentration between 0.005 mg/ml and 0.02 mg/ml, more preferably of 0.01 mg/ml,
• Optionally, n-Dodecyl-β-D-maltoside, preferably at a concentration between 0.1% w/v and 1% w/v, more preferably of 0.5% w/v, and/or glycerol, preferably at a concentration between 0.05% w/v and 0.2% w/v, more preferably of 0.1% w/v,
• Water.